stockrow
Wednesday 11 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
13.12
0.03
−0.23%
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Total debt
Vir Biotechnology, Inc.'s total debt at the end of fiscal 2022 was $128.0M, down 7.25% from $138.0M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $128.0M. Vir Biotechnology, Inc. ranks 71st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $128.0M | (7.25%) |
| FY2021 | $138.0M | 94.37% |
| FY2020 | $71.0M | 7,000.00% |
| FY2019 | $1.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $128.0M | (3.03%) |
| Jun 2023 | $132.0M | 3.13% |
| Mar 2023 | $128.0M | 0.00% |
| Dec 2022 | $128.0M | (2.29%) |
| 12 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| VIR Vir Biotechnology, Inc. | $128.0M |
| REPL Replimune Group, Inc. compare | $121.2M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $5.5M |
| ZYME Zymeworks Inc. compare | $278.0K |
| IMNM Immunome, Inc. compare | $228.0K |
| NAMS NewAmsterdam Pharma Company N.V. compare | $94.9K |
| RXRX Recursion Pharmaceuticals, Inc. compare | $93.0K |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement